Novartis, Pfizer, and Eli Lilly enter the market in high profile to see how pharmaceutical companies play "Internet +"

drug collection "Buddhist" multinational pharmaceutical enterprises, the third into the Expo have been working with the domestic Internet pharmaceutical platform hand in hand!

JD.com Health, through the Hong Kong Stock Exchange listing hearing, will become the third listed Internet health care platform after Ping An Good Doctor, Ali Health!The high-gloss moment of China's Internet and medicine is coming. Between 2015 and 2019, the out-of-hospital pharmaceutical market is expanding at a compound annual rate of 10.8 percent, while online sales are growing at a compound annual rate of 30.4 percent, according to the Frost Sullivan report. In 2019, 25.8% of China's total retail sales of consumer goods have been distributed online, while only 7.6% of out-of-hospital drug sales will be distributed online, and Frost Sullivan predicts that by 2030, 27.5% of medicines will be distributed online through off-the-go drug sales channels.

01 Gifeitini online JD.com PharmacyIt is nothing new for multinational pharmaceutical companies to work with domestic Internet giants. Its cooperation aims to focus more on patient education, slow disease management, but with the implementation of the collection, multinational pharmaceutical companies on the Internet platform demand will be more pragmatic - direct online e-commerce platform sales.For example, in May this year, Lilly Pharmaceuticals announced the entry of 1 drug network online diabetes management platform, in addition to diabetes management and online disease education, but also clearly proposed that Lilly China's multi-diabetic drug portfolio will be provided to 1 drug network supply channels to further enhance patient access to drugs.Not only that, multinational pharmaceutical companies have also opened up the popularization of the original research drug channels speed.Most typically, on September 19th this year, AstraZeneta's lung cancer drugs Gifeitinib (Irisha) and Oztini (Terisha) went online in a "self-employed mode" at JD.com Pharmacy, allowing cancer patients to buy the drug at home.In the 2018 "4-plus-7" pilot city volume procurement, Giffeitini won the bid at 54.7 yuan/piece, and in September 2019, AstraZeneone also won the bid at 54.7 yuan/piece in the results of the Alliance regional drug collection, while Zhengda Tianqing and Qilu Pharmaceutical's Gifeitini tablets won the bid at 45 yuan/piece and 25.7 yuan/piece, respectively. In the "4 plus 7" renewal work, Zhengda Tianqing and Qilu Pharmaceuticals in Chengdu and Fujian regions, respectively, to replace AstraZeneta won the Jifeitini film selection.AstraZeneza's Gifeitini has been seeing a decline in sales since Q2 began in 2019. AstraZeneta reported second-quarter sales of $70m, down 41 per cent from a year earlier, according to AstraZeneta's 2020Q2 results. It is understood that the domestic currently has Qilu Pharmaceuticals, Hengrui Pharmaceuticals, Zhengda Tianqing, Colum Pharmaceuticals, Yangzijiang and Tranno Pharmaceuticals and other enterprises Ofatini was approved for listing, and as as a result of consistent evaluation, AstraZeneone original research products market is bound to suffer further impact. Online market is becoming an important marketing channel that multinational pharmaceutical companies have to consider.

02 is a new option that has high hopesAt this year's Expo, Novarma Oncology, Pfizer China, Sveya China and other multi-national pharmaceutical companies signed a strategic cooperation agreement with Ali Health, in the field of cooperation clearly put forward the words "Internet plus medicine" services and prescription drug cooperation;With the "Internet plus" health care payments actively promoted, "Internet plus medical" ecology is expected to be closed, Everbright Securities believes that in the context of policy promotion and increased demand, the Internet medical industry is expected to usher in multiple catalysis in 2020, the industry accelerated development of the inflection point is coming.The attention of multinational pharmaceutical companies to the Internet innovation platform began to increase. The standout performance is undoubtedly Pfizer's strong. As Pfizer's newly established business unit in 2019, it is responsible for many of Pfizer's original heavy-duty bomb drugs that have exceeded the patent protection period, such as Lipto, Live Hi, Wan Aico and many other well-known products. But Pfizer has embarked on a radical internal overhaul this year against a backdrop of performance-stressed performance, as both Liputo and Live Magpie failed to make the cut in the 4-plus-seven series.In June, Pfizer announced a restructuring of its Greater China organizational structure, splitting its China business team into three divisions: hospital sales, retail and innovative Internet medical services. This is the first time that Pfizer, the "cosmic pharmaceutical company", has been singled out as a single division, becoming the second multinational pharmaceutical company to directly promote Internet healthcare projects, following AstraZeneta's Internet healthcare strategy program.This time, Pfizer will improve its innovative Internet service business to the hospital group, retail group equivalent department, report directly to the president, enough to show that Pfizer's emphasis on Internet channels.In addition, multinational pharmaceutical executives are beginning to move to the Internet and medical platforms.   The usual places for multinational pharmaceutical executives to leave are domestic innovative pharmaceutical companies, or start-ups. But this year, the Internet pharmaceutical platform has become a new choice for multinational pharmaceutical executives, driven by the introduction of 4-plus-seven volume purchases, the emergence of innovative drugs, and the outbreak. On May 6, Guo Anfeng, former vice president of the oncology division of Shishi Shiguibao, took over as chief innovation officer of 1 Pharmaceutical Network, fully responsible for the operation and innovation of the company's Internet medical platform. He has worked for a number of multinational pharmaceutical companies including Pfizer, Bayer, AstraZeneta and BMS. (E drug manager)